Avior Wealth Management LLC Has $327,000 Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Avior Wealth Management LLC lifted its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 3.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,473 shares of the biopharmaceutical company’s stock after buying an additional 131 shares during the period. Avior Wealth Management LLC’s holdings in Intra-Cellular Therapies were worth $327,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of Intra-Cellular Therapies during the third quarter worth approximately $2,436,000. Whalen Wealth Management Inc. acquired a new stake in shares of Intra-Cellular Therapies during the 3rd quarter valued at $219,000. LMR Partners LLP boosted its stake in shares of Intra-Cellular Therapies by 96.2% during the 3rd quarter. LMR Partners LLP now owns 31,177 shares of the biopharmaceutical company’s stock valued at $2,281,000 after buying an additional 15,288 shares during the period. Swiss National Bank grew its holdings in shares of Intra-Cellular Therapies by 8.1% during the 3rd quarter. Swiss National Bank now owns 185,500 shares of the biopharmaceutical company’s stock valued at $13,573,000 after acquiring an additional 13,900 shares in the last quarter. Finally, Simplify Asset Management Inc. increased its stake in shares of Intra-Cellular Therapies by 66.6% in the third quarter. Simplify Asset Management Inc. now owns 30,883 shares of the biopharmaceutical company’s stock worth $2,260,000 after acquiring an additional 12,346 shares during the last quarter. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on ITCI shares. UBS Group lowered their target price on Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $130.00 price target on shares of Intra-Cellular Therapies in a research note on Monday, September 16th. Morgan Stanley raised their price objective on shares of Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. The Goldman Sachs Group decreased their target price on shares of Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. Finally, JPMorgan Chase & Co. raised their price target on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an “overweight” rating in a report on Monday, November 4th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, Intra-Cellular Therapies presently has an average rating of “Moderate Buy” and an average price target of $97.23.

Intra-Cellular Therapies Stock Performance

Shares of NASDAQ ITCI opened at $85.69 on Friday. The stock has a market cap of $9.08 billion, a PE ratio of -98.49 and a beta of 0.97. The business has a fifty day moving average of $79.05 and a two-hundred day moving average of $74.66. Intra-Cellular Therapies, Inc. has a 52-week low of $58.14 and a 52-week high of $93.45.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). The firm had revenue of $175.40 million during the quarter, compared to the consensus estimate of $172.30 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business’s revenue was up 39.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.25) EPS. Analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Insider Buying and Selling

In other news, President Michael Halstead sold 22,869 shares of the company’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total transaction of $2,038,085.28. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Sharon Mates sold 40,513 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $73.58, for a total transaction of $2,980,946.54. Following the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at approximately $78,754,807.82. The trade was a 3.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 97,778 shares of company stock worth $7,524,436 in the last 90 days. Corporate insiders own 2.60% of the company’s stock.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.